Many patients with advanced cancer develop bone metastases, with pain as a common, devastating consequence. Adequate treatment is important to maintain quality of life. Radiotherapy is the standard treatment for patients with painful bone metastases. Metaanalyses of radiotherapy trials have consistently shown a pain response rate of approximately 60% implying that many patients are treated insufficiently. It would be worthwhile to identify patients who will not respond to radiotherapy as these patients might be candidates for other treatments. Furthermore, better understanding and identification of the patients who do not respond to radiation, might help in the development of innovative treatments as alternative or addition to standard (radiation) treatment options. We studied the relationship between patient and treatment characteristics and pain response in patients with metastatic bone disease, with the aim to construct a prediction model to guide individualized treatment decision-making.
Conclusion:
Primary tumor, performance status, baseline pain score, and analgesic use are associated with pain response in patients with bone metastases. However, combining these factors in a prediction model showed poor discrimination limiting its use in clinical practice. Response rates after radiotherapy are moderate, and its prediction is difficult, which shows the need for development of innovative treatments for patients with bone metastases. Purpose or Objective: To present the observed comparative advantages of the single fraction versus long course radiation therapy in the palliative treatment of bone metastasis, in the conditions of technological resources limited to one national center equipped with only cobalt machines.Purpose: To present the observed comparative advantages of the single fraction versus long course radiation therapy in the palliative treatment of bone metastasis, in the conditions of technological resources limited to one national center equipped with only cobalt machines.
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Material and Methods:
The Radiation Therapy of Mother Theresa University Hospital Center, the unique public center providing RT in the country, performed a study comparing single dose of 8 Gy/1fr. versus 20 Gy/5fr. and 30gy/10fr. enrolling 110 patients during a time period of five years (2007 -2012) . Factors for the treatment choice between available options were age, pain level, effect of narcotics and need for assistance as well as time and cost effectiveness. Pain relief was assessed based on the patient perception expressed during the follow up visits, 2 weeks, 4 weeks and 12 weeks after the treatment and subsequently every 12 weeks for a period of 48 weeks. Qualitative data from the follow up visits were classified in a scale of 10 points.
Results:
The complete pain relief was attained for 90 patients or 81.8% out of 110 patients, subject to this study. From this number, 33 patients were treated with single shot, 31 with 20 Gy/5 fraction and 46 with 30Gy/10fr. The percentage of patients benefiting partial pain relief varied from 17.4 to 19.5 which indicate also similar results from the available treatment regimes. Therefore, it wasn't evidenced significant difference between the treatment options as regard to the patients achieving complete or partial pain relief. Further, the toxicity level scored 2-3 grade for all the treatment regimes used. In addition, the patients demonstrated similar median survival from 8 to 10 months for the three options.
Conclusion:
The findings of the study indicate that single fraction 800cGy/1fr is a treatment option with similar effects with the multiple fractions 20Gy/5fr and 30Gy/10fr. It can be used as more time and cost effective standard treatment especially for patients presenting higher level of pain and more in need for assistance including elder and those more distant from the treatment centers.
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Phase II study of short-course accelerated palliative radiotherapy for complicated bone metastases G. Torre ESTRO 35 2016 S667 ________________________________________________________________________________ Material and Methods: A phase II clinical trial was planned based on optimal two-stage Simon's design. Eligibility criteria included patients with an Eastern Cooperative Oncology Group (ECOG) performance status of ≤3. The primary endpoint was to evaluate the symptoms response rate produced by a radiotherapy regimen based on the delivery of 4 radiotherapy fractions (5 Gy per fraction) with a twice daily fractionation in two consecutive days.
Results:
Twenty-nine patients were enrolled in this trial. Characteristics of the patients were: male/female: 16/13; median age: 66 years (range: 46-87). ECOG performance status was <3 in 25 patients (86.2%). With a median follow-up time of 5.0 months (range, 1 to 36 months), 9 G1-2 gastrointestinal (31%), 2 G1 haematological (6.8%) and 6 G1 skin (20.7%) toxicities were recorded. Only 1 patient (3.4%) experienced G3 acute gastro-intestinal toxicity. Of 29 symptomatic patients, 27 showed an improvement or resolution of baseline symptoms (overall palliative response rate: 92.6%). Three-month overall survival was 92.2% (median survival time: not reached). In 25 patients with pain, a significant reduction of this symptom was recorded in terms of Drug Score (mean baseline Drug Score vs mean Drug Score at follow-up: 5.3 vs 4.0; p=0.04).
Conclusion:
Short-course accelerated radiotherapy on complicated bone metastases (20 Gy in twice daily fractions for 2 consecutive days) is tolerated and effective in terms of symptom relief. A phase III comparison against a standard palliative regimen (30 Gy in 10 fractions) has been planned in this patient population. Purpose or Objective: More than 90% of patients with metastatic castration resistant prostate cancer (CRPC) have radiologic evidence of bone metastases. Radium-223 dichloride therapy showed improved overall survival, quality of life and symptom control in patients with symptomatic bone metastases. Aim of the present study is to evaluate clinical course of patients treated in our centre including biochemical and imaging response.
EP-1435 Radium223 in castration resistant prostate cancer with bone metastases: preliminary clinical results
G. Zanirato Rambaldi
Material and Methods:
Since November 2014 we started the treatment of symptomatic bone metastatic CRPC patients with Radium-223 dichloride (50kBq/kg, every 4 weeks). Before and after every administration the following parameter were recorded: PSA and alkaline phosphatase (ALP) values, pain numerical rating scale (NRS), performance status (ECOG scale), analgesic therapy and side effects (graded according to the CTCAE v. 4 classification). A whole body scintigraphy was performed before and one month after the treatment.
Results: Twenty patients (total: 70 administrations) were treated. All patients showed increased PSA value and reduced ALP values. Performance status, evaluated with ECOG scale, was improved in all patients. Pain control was excellent, with reduction of NRS and analgesic therapies in all patients. Most patients showed only G1 toxicity: anaemia (15 pts), fatigue (3 pts), diarrhea (1 pt), nausea (1 pt), and pain flare-up (6 pts).
Eight patients completed the 6 planned cycles of therapy. Six patients discontinued treatment due to adverse events: anaemia (2 pts), pathological fracture of the femur (1 pt), severe bleeding (2 pts) and complications in uncontrolled diabetes (1 pt). The other patients are still under treatment. Whole body scintigraphy performed one month after the end of the treatment demonstrated in all patients a reduced intensity and number of uptake areas without correlation with PSA values.
Conclusion: Treatment with Radium 223 in patients with CRPC and symptomatic bone metastases was tolerated in the majority of patients. High response rates in terms of symptom control and QoL improvement were recorded.
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The superior vena cava syndrome (SVCS): role of the radiotherapy M.S. Mariaquila Santoro
